Benzinga | Aug 5, 2020 04:40PM EDT

Sarepta Therapeutics Q2 EPS $(1.51) Beats $(1.72) Estimate, Sales $111.30M Miss $118.78M Estimate

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(1.51) per share which beat the analyst consensus estimate of $(1.72) by 12.21 percent. This is a 81.93 percent decrease over losses of $(0.83) per share from the same period last year. The company reported quarterly sales of $111.30 million which missed the analyst consensus estimate of $118.78 million by 6.30 percent. This is a 17.57 percent increase over sales of $94.67 million the same period last year.